- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06179017
Endovascular Treatment for Mild Stroke With Acute Anterior Circulation Large Vessel Occlusion
December 19, 2023 updated by: Wen-huo Chen, Zhangzhou Municipal Hospital
Endovascular Treatment for Mild Stroke With Acute Anterior Circulation Large Vessel Occlusion:a Multicenter Randomized Controlled Trail
Exploring the Efficacy and Safety of Emergent Endovascular Treatment in Patients with Mild Ischemic Stroke Caused by Acute Anterior Circulation Large Vessel Occlusion based on Perfusion Imaging Screening
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This study aims to select suitable patients with mild AIS caused by anterior circulation LVO with mismatch volume of the ischemic penumbra based on screen of cerebral perfusion imaging.
It is a prospective, multicenter, endpoint-blinded, randomized controlled trial design, and aim to explore the efficacy and safety of EVT for mild AIS patients with anterior circulation large vessel occlusion within 24 hours of onset.
Study Type
Interventional
Enrollment (Estimated)
300
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Wenhuo Chen, MD
- Phone Number: +8613806906089
- Email: 13806906089@126.com
Study Contact Backup
- Name: Tingyu Yi, MD
- Phone Number: +8615859635985
- Email: siyuyufen@163.com
Study Locations
-
-
Fujian
-
Zhangzhou, Fujian, China, 363000
- Zhangzhou Municipal Hospital
-
Contact:
- Wen-huo Chen, MD
- Phone Number: 13806906089
- Email: 13806906089@126.com
-
Principal Investigator:
- Pengfei Yang, MD
-
Principal Investigator:
- Zeguang Ren, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria Inclusion Criteria
- Age 18-80 years old;
- Symptoms onset or last known well to randomization is within 24 hours.
- Clinical diagnosis of acute ischemic stroke due to anterior circulation intracranial large vessel occlusion (LVO) (including intracranial internal carotid artery [ICA], middle cerebral artery [MCA] M1 segment, MCA M2 segment, with or without ipsilateral extracranial ICA occlusion) confirmed on Computerized tomography angiography (CTA) or Magnetic resonance imaging angiography (MRA) ;
- Baseline NIHSS score <6 before randomization (including cases with NIHSS ≥6 at onset but improves before randomization);
- ASPECTS score ≥6 based on Non-contrast CT (NCCT) before randomization, and computerized tomography perfusion (CTP) or magnetic resonance imaging perfusion (MRP) imaging presented infarct core volume (relative cerebral blood flow (rCBF) <30%/DWI-ADC<620) ≤50ml, and mismatch volume (Tmax>6 seconds volume - rCBF <30% /DWI-ADC<620) ≥50mL;
- The patient or their legal representatives voluntarilysigned the informed consent form.
Clinical Exclusion Criteria
- Premorbid Rankin Scale (mRS) score ≥ 1;
- Known allergy to iodine, heparin, anaesthesia, or other definite contraindication to receiving endovascular treatment (EVT) procedure;
- Patient has severe or fatal co-morbidities that could interfere with outcome assessments and follow-up (such as malignant tumor, severe heart failure, or renal failure, or life expectancy less than 6 months);
- Poorly controlled hypertension (systolic blood pressure >220 mmHg or diastolic blood pressure >120 mmHg);
- Baseline blood glucose <50mg/dL (2.78 mmol/L) or >400mg/dL (22.20 mmol/L);
- Known bleeding tendencies, including but not limited to platelet count <100×109/L; received heparin treatment within 48 hours with an activated partial thromboplastin time (APTT) ≥35s; recent oral anticoagulant therapy with international normalized ratio (INR) >3; Note: Patients without a history of coagulation abnormalities or without suspicion of coagulation abnormalities do not need to wait for laboratory test results before enrollment;
- Seizures at stroke onset or during the course, hard to accurately judge the baseline NIHSS score;
- Female who is known to be pregnant, lactation, or tested positive for pregnancy at time of admission;
- Currently participating in another investigational drug study or medical device treatments that may interfere with the results of this study;
- Other conditions deemed unsuitable for participation, in the opinion of the investigator, or that may pose significant risks to the patient if participating the study.
Imaging Exclusion Criteria:
- Evidence of intracranial hemorrhage on CT/MRI, including cerebral parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, and subdural/extradural hemorrhage;
- Significant midline displacement, hernia of brain, or ventricular mass effect with midline displacement confirmed on CT/MRI;
- Anticipated impossibility to complete endovascular treatment, such as vascular tortuosity, severe vascular wall calcification, etc.;
- Aortic dissection;
- Multiple intracranial large vessel occlusions confirmed by CTA or MRA, unable to clearly identify the symptomatic vessel, such as bilateral MCA occlusions or occlusions involving both the MCA and basilar artery;
- Suspected or confirmed occluded artery is non-acute occlusion.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention Group:Endovascular treatment
Interventionist choose the optimal EVT strategy and device based on the patient's condition and local guidelines.
This may include, but not limited to, stent-retriever thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation and so on.
The EVT regimen and relevant time points will be accurately recorded.
The patient will receive the best medical treatment according to the local guidelines.
|
Intervention Group:Interventionist choose the optimal endovascular treatment (EVT) strategy and device based on the patient's condition and local guidelines.
The patient will receive the best medical treatment according to the local guidelines.
|
Placebo Comparator: Control group: Best medical treatment
Patients will receive the best medical treatment according to local guidelines, including antiplatelet agents, anticoagulants, thrombolysis, etc., but not any EVT.
In the control arm, rescue EVT is allowed in patients with disease progression leading to an increase in NIHSS≥4 and excluding the impact of non-stroke factors, and the onset-to-treatment time is within 24 hours.This may include, but not limited to, stent-retriever thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation and so on.
|
Best medical treatment:Patients will receive the best medical treatment according to local guidelines, including antiplatelet agents, anticoagulants, thrombolysis, etc., but not any EVT.
In the control arm, rescue EVT is allowed in patients with disease progression leading to an increase in NIHSS≥4 and excluding the impact of non-stroke factors, and the onset-to-treatment time is within 24 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the rate of excellent outcome at () days
Time Frame: 90±7 days and 365±30 days
|
mRS score 0-1
|
90±7 days and 365±30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
mRS shift
Time Frame: 90±7 days and 365±30 days
|
distribution of mRS scores
|
90±7 days and 365±30 days
|
proportion of subjects with good neurological function prognosis
Time Frame: 90±7 days and 365±30 days
|
mRS score 0-2
|
90±7 days and 365±30 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the rate of symptomatic intracranial hemorrhage
Time Frame: within 48 hours
|
according to the Heidelberg criteria
|
within 48 hours
|
rate of early neurological deterioration
Time Frame: within 7 days
|
an increase in NIHSS≥4 or an increase of ≥2 in any individual item
|
within 7 days
|
mortality
Time Frame: 90±7 days and 365±30 days
|
death
|
90±7 days and 365±30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Wenhuo Chen, MD, Zhangzhou Municipal Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
January 1, 2024
Primary Completion (Estimated)
August 31, 2027
Study Completion (Estimated)
December 31, 2027
Study Registration Dates
First Submitted
December 2, 2023
First Submitted That Met QC Criteria
December 19, 2023
First Posted (Estimated)
December 21, 2023
Study Record Updates
Last Update Posted (Estimated)
December 21, 2023
Last Update Submitted That Met QC Criteria
December 19, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MILD-MT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endovascular Treatment
-
Beijing Tiantan HospitalRecruitingBasilar Artery Occlusion | Endovascular TreatmentChina
-
Xuanwu Hospital, BeijingPeking University First Hospital; Changhai Hospital; Xiangya Hospital of Central... and other collaboratorsRecruitingEndovascular Treatment | Infrapopliteal Artery Occlusive DiseaseChina
-
Tao ZhangCompletedEndovascular Repair of Aortic Aneurysm | Endovascular Treatment of Arteriosclerosis Obliterans of Lower ExtremitiesChina
-
RenJi HospitalUnknownPeripheral Artery Disease | Endovascular Treatment
-
First People's Hospital of HangzhouShanghai Zhongshan Hospital; RenJi Hospital; Chengdu University of Traditional... and other collaboratorsRecruitingSafety Issues | Efficacy, Self | Lower Extremity Problem | Thromboembolic Disease | Endovascular TreatmentChina
-
University Health Network, TorontoPhilips HealthcareUnknownEndovascular ProceduresCanada
-
Wen-huo ChenCompletedEndovascular TreatmentChina
-
Wen-huo ChenFirst People's Hospital of ShenyangRecruitingEndovascular TreatmentChina
-
General Hospital of Shenyang Military RegionCompletedStroke | Endovascular TreatmentChina
-
University of North Carolina, Chapel HillWithdrawnChanges in Renal Artery Movement Due to Respiration Before and After Fenestrated Endovascular RepairFenestrated Endovascular Aortic Repair
Clinical Trials on Experimental group:Intervention Group
-
Finis Terrae UniversityNot yet recruitingPostoperative Pain | Respiratory ComplicationChile
-
Virginia Commonwealth UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedChronic Low Back Pain | Fear of Pain | Fear of InjuryUnited States
-
Riphah International UniversityCompletedSports Physical TherapyPakistan
-
Ataturk UniversityArtvin Coruh UniversityCompleted
-
Istanbul University - Cerrahpasa (IUC)Completed
-
Riphah International UniversityRecruitingEffects of Strength Training on Freestyle Swimming Performance and Core Muscles Strength in SwimmersSports Physical TherapyPakistan
-
Cristian AlvarezUniversidad de La FronteraCompleted
-
RezoluteActive, not recruitingDiabetic Macular EdemaUnited States
-
Dr. Sobia HasanNot yet recruitingDiabetic Neuropathies
-
European Institute of OncologyRecruiting